Trial Profile

A study evaluating secukinumab in patients with inflammatory bowel diseases (IBD)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secukinumab (Primary)
Indications Axial spondyloarthritis; Crohn's disease; Psoriasis; Sacroiliitis; Spondylarthritis; Ulcerative colitis
Focus Adverse reactions
Acronyms MISSIL

Most Recent Events

03 Nov 2021 Results (n=31; during January, 1st 2016 and December, 31st 2019) assessing new-onset inflammatory bowel diseases (new IBD) in patients treated with interleukin 17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life, published in the Rheumatology.
06 Jun 2020 Results (N=24), presented at the 21st Annual Congress of the European League Against Rheumatism
23 Jun 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com